Elicurium (atracurium besylate): Uses, Dosage & Side Effects

What it's for (Indications)

Atracurium besylate is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in surgical procedures across a wide range of patient populations.
It is also used to provide skeletal muscle relaxation during various surgical interventions requiring an immobile operative field, such as abdominal, thoracic, and orthopedic surgeries.
Beyond the operating room, atracurium is critically employed in the intensive care unit (ICU) to facilitate mechanical ventilation, particularly in patients with acute respiratory distress syndrome (ARDS), status asthmaticus, or other conditions where muscle paralysis is required to optimize ventilator synchrony and reduce oxygen consumption.
Its use ensures proper management of the airway and supports adequate gas exchange.
The administration of atracurium must always be accompanied by appropriate levels of sedation and analgesia, as the drug itself does not affect consciousness or pain perception.
It is suitable for short to intermediate duration procedures due to its relatively predictable onset and offset of action.

Dosage Information

Type	Guideline
Standard	Atracurium besylate must be administered intravenously only; intramuscular administration is strictly contraindicated. To avoid distress, do not administer before unconsciousness is induced. Do not mix in the same syringe or administer simultaneously with alkaline solutions. Use of a peripheral nerve stimulator is recommended to optimize usage and assess recovery. For adults, a typical bolus dose for intubation and maintenance of neuromuscular block is 0.4 to 0.5 mg/kg.

Type

Guideline

Standard

Atracurium besylate must be administered intravenously only; intramuscular administration is strictly contraindicated. To avoid distress, do not administer before unconsciousness is induced. Do not mix in the same syringe or administer simultaneously with alkaline solutions. Use of a peripheral nerve stimulator is recommended to optimize usage and assess recovery. For adults, a typical bolus dose for intubation and maintenance of neuromuscular block is 0.4 to 0.5 mg/kg.

Safety & Warnings

Common Side Effects

Adverse reactions observed include those suggestive of histamine release, such as bronchial secretions, wheezing, and hypotension.
Hypotension was noted more frequently in patients with significant cardiovascular disease.
The overall incidence of clinically important adverse reactions was approximately 0.
8% in clinical trials.
Regarding pregnancy and lactation, consult your doctor before using this medication.
Driving should be avoided due to potential impairment of ability.

Serious Warnings

Black Box Warning: Atracurium besylate, a potent neuromuscular blocking agent, does not possess analgesic or sedative properties, and its administration must always be accompanied by adequate sedation and analgesia. Patients remain fully conscious and aware unless effectively sedated. This medication must only be administered by, or under the supervision of, experienced clinicians skilled in airway management and respiratory support, and only when immediate availability of resuscitative equipment and personnel is assured. Its use results in dose-dependent paralysis of skeletal muscles, including those essential for respiration. Therefore, mechanical ventilation is mandatory until full spontaneous respiration is recovered. Serious adverse events, including profound and prolonged muscle paralysis, respiratory depression, and anaphylaxis, can occur. Use with extreme caution in patients with neuromuscular diseases (e.g., myasthenia gravis, Eaton-Lambert syndrome), severe electrolyte disturbances, or conditions that may potentiate neuromuscular blockade, as these patients may exhibit increased sensitivity and prolonged recovery. Histamine release leading to transient hypotension, flushing, and bronchospasm may occur, particularly with rapid bolus administration.
Atracurium must be administered only with adequate general anesthesia and should not be given before unconsciousness has been induced to avoid patient distress.
It should not be mixed in the same syringe or administered simultaneously with alkaline solutions (e.
g.
, barbiturate solutions).
Intramuscular administration is not recommended due to potential tissue irritation and lack of supporting clinical data.
The use of a peripheral nerve stimulator is advised for optimal dosage and monitoring of recovery.
Pregnancy and lactation require medical consultation due to unruled out risks.
Driving should be avoided as it may affect your ability.

How it Works (Mechanism of Action)

Atracurium besylate is a non-depolarizing neuromuscular blocking agent that acts at the neuromuscular junction. Its primary mechanism involves competitively binding to the nicotinic cholinergic receptors located on the motor end-plate of skeletal muscle fibers. By occupying these receptor sites, atracurium prevents the binding of acetylcholine, the endogenous neurotransmitter responsible for transmitting nerve impulses to muscle fibers. This competitive antagonism effectively blocks the depolarization of the motor end-plate, thereby inhibiting neuromuscular transmission and leading to dose-dependent flaccid paralysis of skeletal muscles. A distinctive feature of atracurium's pharmacokinetics is its primary elimination pathway through Hofmann elimination (a non-enzymatic chemical degradation at physiological pH and temperature) and ester hydrolysis, largely independent of renal or hepatic function. This unique metabolic profile can be advantageous in patients with significant renal or hepatic impairment, offering a more predictable duration of action compared to agents heavily reliant on organ clearance. The onset of action is typically within 2-3 minutes, with a clinically significant duration of paralysis lasting approximately 20-35 minutes following a standard intubating dose, before spontaneous recovery begins.